These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1422 related articles for article (PubMed ID: 27437888)

  • 1. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors for INR-control in a well-managed warfarin treatment setting.
    Björck F; Kadhim H; Själander A
    J Thromb Thrombolysis; 2019 Feb; 47(2):227-232. PubMed ID: 30411185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
    Guo Y; Wang H; Tian Y; Wang Y; Lip GYH
    Chest; 2015 Jul; 148(1):62-72. PubMed ID: 25501045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.
    Sandén P; Renlund H; Svensson PJ; Själander A
    Thromb Haemost; 2017 Jan; 117(1):27-32. PubMed ID: 27652593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.
    Sjögren V; Grzymala-Lubanski B; Renlund H; Friberg L; Lip GY; Svensson PJ; Själander A
    Thromb Haemost; 2015 Jun; 113(6):1370-7. PubMed ID: 25716771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
    Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW
    Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
    JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation.
    Xian Y; O'Brien EC; Liang L; Xu H; Schwamm LH; Fonarow GC; Bhatt DL; Smith EE; Olson DM; Maisch L; Hannah D; Lindholm B; Lytle BL; Pencina MJ; Hernandez AF; Peterson ED
    JAMA; 2017 Mar; 317(10):1057-1067. PubMed ID: 28291892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
    Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
    Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
    J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
    Lee BH; Park JS; Park JH; Park JS; Kwak JJ; Hwang ES; Kim SK; Choi DH; Kim YH; Pak HN
    J Cardiovasc Electrophysiol; 2010 May; 21(5):501-7. PubMed ID: 20021521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.